Stock Price & Analysis

Based on the provided data, TECH stock is showing bearish signals with a 3.98% decline in regular market trading to $69.92, despite recent analyst upgrades. While Scotiabank raised the price target to $90 citing strong Q2 results, insider sentiment remains negative with recent selling activity by executives.

Technical Analysis The stock is currently trading below its 20-day moving average of $74.82, indicating short-term bearish momentum. With an RSI of 38.31, the stock is approaching oversold territory but hasn't reached extreme levels yet.

Fundamental Analysis

• P/E ratio: 77.32 (indicating relatively high valuation)
• Market cap: $11.53B
• Recent insider selling: CEO Kim Kelderman sold 13,392 shares for approximately $1 million

Analyst Consensus Recent analyst actions:

• Scotiabank: Outperform, PT $90 (Feb 6)
• KeyBanc: Buy, PT $90 (Feb 6)
• RBC Capital: Hold, PT $80 (Feb 6)

Market Context Healthcare sector showed weakness today with a 0.4% decline, with Bio-Techne being one of the notable decliners (-4.5%).

Given the current technical weakness, negative insider sentiment, and high valuation multiple, selling pressure may continue in the near term. Consider waiting for technical stabilization before establishing new positions.

Based on the latest data and analyst reports, here's the price prediction for TECH stock in 2025:

TECH stock is expected to reach $90 by mid-2025, supported by Scotiabank's recent price target upgrade from $88 and strong Q2 results showing earlier-than-expected pickup in demand from large biopharma customers. However, near-term headwinds suggest the stock may first test support around $79, which is the current consensus price target among analysts maintaining a Hold rating. The stock is currently trading at $69.92, indicating potential upside of approximately 29% to reach the most bullish target of $90.

The S1 support level for TECH Stock is $68.87 ,The R1 resistant level for TECH Stock is $77.76.

As of the end of day on 2025-02-11, the price of TECH Stock was $69.5.

The target price for TECH Stock according to analyst rating is 86.33, with the highest price target at 95.00 and the lowest at 75.00. Analysts have a Moderate Buy rating on TECH Stock overall.

The market cap of TECH is $11.1B.

Based on the provided data and context, let's analyze whether the tech sector is currently overvalued:

Market Valuation Analysis:

The tech sector shows several signs of elevated valuations in early 2025:

Key Valuation Metrics:

Signs of Overvaluation:

1. Apple's forward P/E of 36.68 is significantly higher than its historical average, indicating stretched valuations despite slowing growth.

2. Microsoft's P/S ratio of 12.03 is notably high, reflecting aggressive AI-related spending plans of $80 billion in FY2025.

3. The Technology Select Sector SPDR Fund trades at an average P/E of 39x, well above historical norms.

4. Recent market behavior shows concerning similarities to the 2022 tech selloff, with many stocks trading at unsustainable valuations.

5. The sector's valuation appears driven more by AI hype than fundamental improvements, with companies like Meta and Microsoft planning massive AI investments that may not generate immediate returns.

Conclusion: The tech sector shows clear signs of overvaluation, with multiples well above historical averages and fundamentals not fully supporting current prices. The combination of high valuations, aggressive AI spending, and market euphoria suggests increased risk of a correction.

Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Based on analyst reports and market data, TECH stock is projected to reach $90-95 by 2030, driven by continued growth in biopharma demand and AI integration in biotechnology. Recent analyst upgrades from Scotiabank and strong Q2 FY2025 results support this bullish outlook. However, insider selling activity and current high P/E ratio of 77.32 suggest potential near-term volatility.

TECH has a total of 3050 employees.